The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 54 of the 60 sources its claims cite were checked for support.
The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies
Open accessAbstract
Human genetics studies of Alzheimer’s disease (AD) have identified the ABI3 gene as a candidate risk gene for AD. Because ABI3 is highly expressed in microglia, the brain’s immune cells, it was suggested that ABI3 might impact AD pathogenesis by regulating the immune response. Recent studies suggest that microglia have multifaceted roles in AD. Their immune response and phagocytosis functions can have beneficial effects in the early stages of AD by clearing up amyloid-beta (Aβ) plaques. However, they can be harmful at later stages due to their continuous inflammatory response. Therefore, it is important to understand the role of genes in microglia functions and their impact on AD pathologies along the progression of the disease. To determine the role of ABI3 at the early stage of amyloid pathology, we crossed Abi3 knock-out mice with the 5XFAD Aβ-amyloidosis mouse model and aged them until 4.5-month-old. Here, we demonstrate that deletion of the Abi3 locus increased Aβ plaque deposition, while there was no significant change in microgliosis and astrogliosis. Transcriptomic analysis indicates alterations in the expression of immune genes, such as Tyrobp, Fcer1g, and C1qa. In addition to the transcriptomic changes, we found elevated cytokine protein levels in Abi3 knock-out mouse brains, strengthening the role of ABI3 in neuroinflammation. These findings suggest that loss of ABI3 function may exacerbate AD progression by increasing Aβ accumulation and inflammation starting from earlier stages of the pathology.
Overview
CoChat Summary
TL;DR
In 4.5-month-old 5XFAD mice, deletion of the Abi3 locus increased insoluble Aβ40 and fibrillar plaque load without altering overall microgliosis or astrogliosis, while altering immune gene expression and cytokine levels. These findings suggest that loss of ABI3 function may exacerbate early AD-related amyloid and inflammatory pathology.
Key findings
- Insoluble guanidine-extracted Aβ40 was increased 1.6-fold in Abi3-/- cortices, and PBS-soluble Aβ40 was decreased by 61%; RIPA-soluble Aβ42 was significantly increased, while PBS-soluble Aβ42 was significantly decreased with a smaller effect size.
- X34+ fibrillar plaque area and plaque number were significantly increased in Abi3-/- mice, but IBA1+ microglial area and GFAP+ astrocyte area were not significantly different; more GFAP+ cells colocalized with plaques in Abi3-/- mice.
- Transcriptomic analysis found Ctss, Fcer1g, Tyrobp, C1qa, and Cyba as the most significantly upregulated genes and Ap3b2 as the most downregulated; 32 DEGs were shared between young and old cohorts, with 53 young-specific and 64 old-specific DEGs.
- In PBS-soluble cortical fractions, IL-33 and CCL2 were significantly decreased, while CXCL10 and CCL3 were significantly increased; CXCL2 did not differ. In RIPA-soluble fractions, CXCL10, CCL3, and CCL2 were significantly increased.
Methods
- Abi3 knock-out mice were crossed with 5XFAD mice to generate 5XFAD;Abi3+/+ and 5XFAD;Abi3-/- mice; female 4.5-month-old mice were used.
- Cortical tissue was analyzed by Western blot, MSD electrochemiluminescence for Aβ40/Aβ42 and cytokines, X34/IBA1/GFAP immunohistochemistry, and NanoString nCounter Mouse AD panel transcriptomics.
- Statistical comparisons used unpaired two-tailed t-tests and Pearson correlations; sample sizes included n=13–16 for Aβ assays, n=9–10 for histology, n=6/genotype for NanoString, and n=14–15 for cytokines.
Limitations
- The paper does not include a dedicated limitations section.
- Evident from the text: experiments used only female 4.5-month-old 5XFAD mice, so findings may not generalize to males, other ages, or other AD models; the paper itself notes conflicting results in TgCRND8 mice and attributes differences partly to distinct familial AD mutations.
- Evident from the text: transcriptomic profiling used the nCounter Mouse AD panel covering 760 genes rather than whole-transcriptome sequencing, and the mechanism linking Abi3 deletion to increased Aβ remains indirect because Aβ production/degradation proteins did not differ and microglial migration impairment was proposed from prior work.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
32 Valid · 0 Not valid · 1 Not checked · 76 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“ABI3 is a microglia-enriched gene (16, 18, 19).”
- Also stated in: § Abstract · boosted
“Because ABI3 is highly expressed in microglia, the brain’s immune cells, it was suggested that ABI3 might impact AD pathogenesis by regulating the immune response.”
§ The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies > Introduction
What the sources say
- Supportedcites [16] Sims, 2017, Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in alzheimer's disease, Nat Genet source
The Gene Expression section reports that ABI3 is more highly expressed in purified cortical microglia/macrophages than in bulk cortex. It also explicitly describes ABI3 as a microglia-enriched gene. (LLM, conf=0.95)
- Supportedcites [18] Turner, 2022, Identification and quantitation of novel ABI3 isoforms relative to alzheimer's disease genetics and neuropathology, Genes source
The Introduction states that ABI3 is expressed primarily by microglia in the human brain. Results §3.3 also reports robust Abi3 expression in mouse microglia, supporting the description of ABI3 as microglia-enriched. (LLM, conf=0.94)
- Supportedcites [19] Satoh, 2017, Microglia express ABI3 in the brains of alzheimer's disease and nasu-hakola disease, Intractable Rare Dis Res source
The Discussion concludes that ABI3 is expressed almost exclusively on a subset of microglia in the brains examined. The Results also report ABI3 staining chiefly in microglia, with no discernible expression in astrocytes, oligodendrocytes, or neurons. These passages support describing ABI3 as microglia-enriched. (LLM, conf=0.92)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Human genetics studies of Alzheimer’s disease (AD) have identified the ABI3 gene as a candidate risk gene for AD.”
- Also stated in: § Introduction · plain
“Recent human genetics studies of AD identified a risk variant in the Abelson interactor family member 3 (ABI3) locus in late-onset AD (LOAD) patients (2, 15–17).”
§ The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies > Abstract
What the sources say
- Supportedcites [2] Bellenguez, 2022, New insights into the genetic etiology of alzheimer's disease and related dementias, Nat Genet source
The GWAS meta-analysis lists a variant at ABI3 (rs616338) associated with Alzheimer’s disease and related dementias, with an odds ratio of 1.32 and P = 2.8 × 10⁻¹⁴. This supports describing ABI3 as a candidate AD risk gene. (LLM, conf=0.93)
- Supportedcites [15] Conway, 2018, ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in caucasians and African americans, Mol Neurodegener source
The Background states that an ABI3 variant had been implicated in Alzheimer’s disease risk, and the Conclusions say this study strengthens evidence for that variant as an AD risk factor. Those passages support describing ABI3 as a candidate AD risk gene. Page numbers are not provided in our copy. (LLM, conf=0.93)
- Supportedcites [16] Sims, 2017, Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in alzheimer's disease, Nat Genet source
The Abstract reports a genome-wide significant risk variant in ABI3 associated with Alzheimer’s disease. It also states that the p.F209 variant consistently increased late-onset Alzheimer’s disease risk across study stages, supporting the description of ABI3 as a candidate risk gene. (LLM, conf=0.95)
- Supportedcites [17] Olive, 2020, Examination of the effect of rare variants in TREM2, ABI3, and PLCG2 in LOAD through multiple phenotypes, J Alzheimers Dis source
The Introduction reports that a human genetics study identified the ABI3 p.S209F variant as a risk variant for late-onset Alzheimer’s disease. The Results also report a significant association between ABI3 and Alzheimer’s disease risk. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These studies have led to the notion that microglia can have differential effects on AD pathology depending on the disease stage.”
- Also stated in: § Introduction · boosted
“Functional studies with microglial AD risk genes also demonstrated that the deletion of these genes could affect AD-related pathologies in different ways, sometimes even in opposite directions (8–14).”
§ The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies > Introduction
What the sources say
- Supportedcites [8] Meilandt, 2020, Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the Abeta42:Abeta40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP alzheimer's mouse model, J Neurosci source
The Introduction explicitly proposes that microglial TREM2 activity may be protective or detrimental depending on disease stage and the pathology present. That supports the citing sentence’s qualified claim that microglia can have different effects on AD pathology across stages. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [9] Jay, 2017, Disease progression-dependent effects of TREM2 deficiency in a mouse model of alzheimer's disease, J Neurosci source
- Partly supportedcites [10] Jay, 2015, TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in alzheimer's disease mouse models, J Exp Med sourceExperimental — accuracy not yet measured
In Results and Discussion (page unavailable), the paper reports that TREM2 deficiency reduced amyloid pathology in 4-month-old AD-model mice, and it describes an age-dependent increase in TREM2-expressing cells around plaques. Those findings link TREM2-associated immune cells to pathology and disease progression, but the paper does not show that microglia have different effects on pathology at different disease stages; it also leaves open whether the implicated cells are microglia or peripheral macrophages. (LLM, conf=0.82)
- Partly supportedcites [11] Lee, 2010, CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two alzheimer's disease mouse models, Am J Pathol sourceExperimental — accuracy not yet measured
The “Microglial Removal of Aβ” section says microglial effects on amyloid pathology vary with activation status and with disease states or experimental conditions. It does not establish that those effects differ specifically by stage of Alzheimer’s disease; a stage-dependent effect is the unsupported part of the claim. (LLM, conf=0.82)
- Supportedcites [12] Puntambekar, 2022, CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in alzheimer's disease, Mol Neurodegener source
The Background (page unavailable) says glial activation evolves as AD pathology develops, and the Conclusions describe microglial activation states as dynamically responding to different pathological features. The Results (page unavailable) also report that CX3CR1 deficiency affects microglial engagement with different plaque types at four versus six months in AD-model mice. Together, these passages support the citing sentence’s cautious, stage-dependent characterization. (LLM, conf=0.88)
- Supportedcites [13] Bemiller, 2017, TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy, Mol Neurodegener source
The Discussion says TREM2 and other innate immune pathways may have detrimental roles in early AD, when Aβ predominates, but beneficial roles later, when tau pathology develops. It identifies a microglial receptor among the pathways discussed, supporting the claim that microglial effects can differ by disease stage. (LLM, conf=0.92)
- Supportedcites [14] Leyns, 2017, TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy, Proc Natl Acad Sci U S A source
The Discussion (page not specified) proposes that TREM2-dependent microglial responses may mitigate amyloid-related toxicity early in AD but promote neurodegeneration after tau pathology begins. It explicitly describes these as possible stage- and pathology-specific effects, supporting the citing sentence’s qualified claim. (LLM, conf=0.92)
boostedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Earlier studies on other microglial AD risk genes reported opposing effects on AD-related pathologies using various animal models at different ages (8–14).”
§ The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies > Discussion
What the sources say
- Supportedcites [8] Meilandt, 2020, Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the Abeta42:Abeta40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP alzheimer's mouse model, J Neurosci source
The Introduction (page unavailable) reports that earlier Trem2-deletion studies found increased, decreased, or unchanged plaque load depending on the mouse model and age. It also describes opposing effects on tau-related pathology in different models, supporting the citing sentence’s summary of varied findings for a microglial AD risk gene. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [9] Jay, 2017, Disease progression-dependent effects of TREM2 deficiency in a mouse model of alzheimer's disease, J Neurosci source
- Partly supportedcites [10] Jay, 2015, TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in alzheimer's disease mouse models, J Exp Med sourceExperimental — accuracy not yet measured
The Results and Discussion section reports that TREM2 deficiency reduced amyloid and tau-related pathology in APPPS1 mice; its discussion contrasts that finding with evidence about TREM2 overexpression and human risk variants. Materials and Methods identifies two AD mouse models, but this paper does not establish opposing pathological effects across different models and ages. It supports one part of the multi-study claim, not the full comparison. (LLM, conf=0.83)
- Partly supportedcites [11] Lee, 2010, CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two alzheimer's disease mouse models, Am J Pathol sourceExperimental — accuracy not yet measured
The Discussion reports reduced amyloid pathology after CX3CR1 deficiency in two AD mouse models, while Microglial Proliferation/Migration (p. 2552) contrasts those findings with a study of younger 3xTg mice. This supports the point that findings differ across models and ages. The paper does not establish CX3CR1 as an AD risk gene or document opposing effects for multiple such genes. (LLM, conf=0.82)
- Partly supportedcites [12] Puntambekar, 2022, CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in alzheimer's disease, Mol Neurodegener sourceExperimental — accuracy not yet measured
The Background reports divergent effects of CX3CR1 deficiency in different AD mouse models: reduced amyloid burden in early disease but worsened tau pathology in a tauopathy model. The Discussion also mentions AD-related microglial genes TREM2 and APOE, but does not report opposing effects of those other genes across models and ages. No page numbers are available in our copy. (LLM, conf=0.85)
- Supportedcites [13] Bemiller, 2017, TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy, Mol Neurodegener source
The Discussion reports that TREM2 deficiency reduced hippocampal amyloid pathology at 4 months but increased amyloid burden at 8 months in APPPS1 and 5XFAD mice. It also contrasts findings in those models with enhanced tau pathology in hTau mice, supporting the cited sentence’s account of differing effects across ages and animal models. (LLM, conf=0.88)
- Partly supportedcites [14] Leyns, 2017, TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) contrasts this study’s protective effect of TREM2 deficiency in a tauopathy mouse model with reports that TREM2 loss worsens amyloid-dependent toxicity in other mouse models. That supports opposing effects across pathologies and models, but the paper does not establish the claim for multiple other microglial AD risk genes or attribute those differences to animals studied at different ages. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As we and others demonstrated in prior studies (22, 23), several genes were significantly downregulated in the Abi3-/- mouse model, including the Gngt2 and Gm10039.”
§ The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies > Discussion
What the sources say
- Supportedcites [22] Karahan, 2021, Deletion of Abi3 gene locus exacerbates neuropathological features of alzheimer's disease in a mouse model of aβ amyloidosis, Sci Advances source
The Results section reports marked downregulation of several genes, explicitly including Gngt2 and Gm10039, in Abi3−/− mice compared with Abi3+/+ mice. The Discussion reiterates the finding. Our copy provides no page numbers for these passages. (LLM, conf=0.90)
- Partly supportedcites [23] Ibanez, 2022, Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways, Alzheimers Res Ther sourceExperimental — accuracy not yet measured
The Results section (‘ABI3 and GNGT2 genes are co-regulated in APP mouse models and in AD’; page unavailable) reports that Gngt2 expression was dramatically reduced in the knockout mice. The Results section on reactive gliosis also lists Gngt2 among downregulated RNAs. Our copy does not mention Gm10039, so it does not support that part of the claim. (LLM, conf=0.85)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
70 more claims · 9 with their cited sources checked
Create a free account to see all 109 claims and every source verdict.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The deletion of Abi3 in mice accelerates Aβ accumulation, decreases microglial migration and clustering around plaques, and reduces LTP due to Aβ accumulation in a mouse model of AD (5XFAD)164,165.”
From The WAVE complex in developmental and adulthood brain disorders (2025) · cites this paper as [165]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, we performed power analyses using our previously published data from 4.5‐ and 8‐month‐old 5XFAD mice to identify the cohort with the least variability. 25 , 26 These analyses identified that female mice showed less variability in pathological measures.”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [25]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, a recent study showed that SPI1 expression has a low correlation between peripheral monocytes and brain microglia60.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [60]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies > Results > Alterations in cytokine levels in Abi3 knock-out mice
“Among these, IL-33 and CCL2 were significantly decreased, whereas CXCL10 and CCL3 were significantly increased in the PBS-soluble fraction of Abi3-/- mouse cortices compared to Abi3+/+ mice ( Figures 4A-D ).”
§ The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies > Results > Alterations in cytokine levels in Abi3 knock-out mice
“(A) IL-33, (B) CXCL10, and (C) CCL3 were significantly increased, whereas (D) CCL2 was decreased in Abi3-/- mice compared to Abi3+/+ mice.”
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 1×
“While microglia transcriptome is associated with a homeostatic state at earlier stages of the disease, they show a gradual transition into a disease-associated state with a unique transcriptomic signature (44).”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
ilastik: interactive machine learning for (bio)image analysis
Berg, S., Kutra, D., Kroeger, T., Straehle, C. N., Kausler, B. X., Haubold, C., Schiegg, M., Ales, J., Beier, T., Rudy, M., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0582-9 · Cited by 3,368
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 2×
“While earlier studies considered gliosis just as a secondary response to Ab accumulation in AD, recent studies have demonstrated that gliosis starts at very early stages of the disease and may play an important role during disease progression (6, 34).”
BackgroundResultMicroglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894 · cited 2×
“These changes were associated with beneficial or harmful effects, depending on the disease stage (7, 35, 36).”
BackgroundLane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
Cited by
Zhang, C., Qi, H., Jia, D., Zhao, J., Xu, C., Liu, J., Cui, Y., Zhang, J., Wang, M., Chen, M., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122457 · Cited by 39
Roy, N., Haq, I., Ngo, J. C., Bennett, D. A., Teich, A. F., Jager, P. L. D., Olah, M., & Sher, F. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02835-6 · Cited by 39
“ABI3 encodes a protein which plays a role in actin cytoskeleton rearrangement and is required for normal microglial migration and phagocytosis [55, 56, 111].”
Takatori, S., Kondo, M., & Tomita, T. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00383-4 · Cited by 29
Tate, M., Wijeratne, H. R. S., Kim, B., Philtjens, S., You, Y., Lee, D., Gutierrez, D. A., Sharify, D., Wells, M., Perez‐Cardelo, M., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14243 · Cited by 21
Self-citationZhang, H., Bi, F., Zhao, P., Cui, H., Tao, X., Zhang, J., Li, C., Cao, Y., Wang, N., & Li, H. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119464 · Cited by 16
Metadata
- Authors
- Karahan, H., Smith, D. C., Kim, B., McCord, B., Mantor, J., John, S. K., Al-Amin, M. M., Dabin, L. C., & Kim, J.
- Affiliations
- Indiana University School of Medicine (US)
- Indiana University Indianapolis (US)
- Corresponding author
- Kim, Jungsu
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-02-21
- Volume
- 14
- Pages
- 1102530-1102530
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC9988916
- OpenAlex
- W4321459283
- Cited by
- 20
- References
- 59
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 5 · 2023: 1
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (R01AG071281, RF1AG074543, R01AG077829, R21AG072738)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- ABI3, Alzheimer's disease, amyloid plaques, microglia, neuroinflammation, 5xFAD mice, amyloidosis, microglial activation, astrocyte activation, cytokines, immune gene expression, C1QA, FCER1G, TYROBP, disease progression
- MeSH terms
- Alzheimer Disease, Amyloidosis, Animals, Brain, Humans, Amyloid beta-Peptides, Microglia, Mice, Knockout, Adaptor Proteins, Signal Transducing, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies. https://app.cochat.ai/papers/10.3389/fimmu.2023.1102530
- The paper
- Karahan, H., Smith, D. C., Kim, B., McCord, B., Mantor, J., John, S. K., Al-Amin, M. M., Dabin, L. C., & Kim, J. (2023). The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1102530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.